EU INCI rules require greater ingredient transparency, including allergens, colorants, and nanomaterials. MoCRA strengthens U.S. oversight through product listing, facility registration, and post-market controls. As a result, global cosmetic companies must manage INCI lists as part of a broader compliance strategy.
INCI List Differences Between EU and U.S.: Why Understanding Matters
The comparison of ingredient labeling requirements between the European Union and the United States remains a central topic in cosmetic regulatory affairs, particularly in the context of global market access. Although both jurisdictions adopt the International Nomenclature of Cosmetic Ingredients (INCI) as a common language, the legal frameworks governing ingredient disclosure differ significantly in their level of prescriptiveness, transparency obligations, and regulatory philosophy.
In the European Union, cosmetic labeling is harmonized and strictly regulated under Regulation (EC) No 1223/2009, which establishes detailed requirements for ingredient listing, allergen disclosure, and consumer information. In contrast, the United States has historically relied on a more flexible system under the Federal Food, Drug, and Cosmetic Act and its implementing provisions (notably 21 CFR Part 701). However, the adoption of the Modernization of Cosmetics Regulation Act of 2022 has introduced a new regulatory paradigm, reinforcing FDA oversight and redefining compliance expectations without fundamentally altering the structure of INCI labeling.
Key Regulatory Differences: Ingredient Order, Allergens, and Transparency
From a technical perspective, several core elements of INCI list construction remain aligned between the two jurisdictions, though important nuances exist. Both the EU and the U.S. require ingredients to be listed in descending order of predominance, with a threshold of 1% below which ingredients may be listed in any order. However, the EU framework provides a more explicit and harmonized interpretation of this rule, ensuring consistency across Member States, whereas U.S. enforcement—now strengthened under MoCRA —relies more heavily on post-market controls and regulatory oversight.
More substantial differences emerge in the area of transparency, particularly regarding fragrance disclosure. The EU imposes mandatory labeling of specific fragrance allergens when they exceed defined thresholds, as set out in Annex III of Regulation 1223/2009 and these requirements have recently been expanded to reflect updated scientific assessments on sensitization risks.
By contrast, U.S. regulations continue to permit the use of generic terms such as “fragrance” or “flavor,” thereby protecting proprietary formulations but limiting transparency at the ingredient level. Importantly, MoCRA establishes the legal basis for future FDA rulemaking on fragrance allergen disclosure, signaling a potential shift toward increased alignment with the EU approach.
Additional divergences concern specific ingredient categories. Colorants, for example, are regulated in the EU through Annex IV with the mandatory use of CI numbers, whereas in the U.S. they fall under a distinct regulatory regime (21 CFR Parts 70–82), including batch certification requirements for certain substances. Similarly, the EU explicitly addresses emerging risk categories such as nanomaterials, requiring both labeling (via the “nano” suffix) and prior safety evaluation by the Scientific Committee for Consumer Safety (SCCS).
The U.S. framework, even after MoCRA, does not impose equivalent labeling obligations, relying instead on general safety substantiation requirements. In this context, MoCRA plays a pivotal role not by modifying labeling syntax, but by strengthening systemic controls: mandatory facility registration, product listing (including ingredient data), adverse event reporting, and the formalization of the “Responsible Person” concept. These elements increase regulatory traceability and create a more robust link between formulation, documentation, and labeling.
Strategic Management of INCI List Differences in Global Markets
In the post-MoCRA regulatory landscape, INCI list differences between the European Union and the United States can no longer be interpreted solely as formal distinctions in labeling rules. Rather, they reflect two systems that, while still distinct in their approach to transparency and risk communication, are gradually converging in terms of regulatory rigor and oversight.
The EU continues to represent the benchmark for prescriptive, consumer-oriented disclosure, particularly with regard to allergens and emerging substances. At the same time, the United States—through MoCRA—is transitioning toward a more structured and enforceable model, where ingredient information is not only declared on the label but also integrated into a broader regulatory framework of accountability and data consistency.
For cosmetic companies operating internationally, this evolution has concrete strategic implications. The management of INCI lists must now be aligned not only with regional labeling requirements but also with upstream regulatory obligations, including product listing, safety substantiation, and post-market surveillance.
In this sense, adopting an EU-aligned labeling strategy may offer advantages in terms of future-proofing and regulatory harmonization, although it may also entail increased disclosure. Ultimately, effective compliance requires a holistic approach in which INCI list differences are addressed as part of an integrated regulatory system, rather than as isolated technical requirements.
If you need support navigating MoCRA requirements, from product listing and facility registration to broader cosmetic compliance obligations, explore our full MoCRA services to see how we can help.
Key Takeaways: EU vs. U.S. INCI List Rules
- EU INCI rules require greater ingredient transparency than the U.S.
- MoCRA strengthens U.S. regulatory oversight without fully aligning labeling with the EU.
- Fragrance allergens, colorants, and nanomaterials are disclosed more strictly in the EU.
- Global cosmetic companies must manage INCI lists as part of broader compliance obligations.
- An EU-aligned labeling strategy can support harmonization and future-proofing.
